FDA takes second action under international collaboration, approves new treatment option for patients with chronic lymphocytic leukemia

November 21, 2019 – Today, as part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the U.S. Food and Drug Administration granted supplemental approval to acalabrutinib for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This new approved indication for Acalabrutinib provides a new treatment option for patients with CLL or SLL as an initial or … (leggi tutto)